AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.
Company Details
Directors and Executives
Announcements
| Title | Date | Type |
|---|---|---|
| AFT updates operating profit guidance to $23m to $25m | Fri, Feb 16 2024 08:30 am | GENERAL |
| Maxigesic IV launched in the United States | Wed, Feb 07 2024 08:30 am | GENERAL |
| AFT further broadens R&D pipeline with new product | Fri, Jan 19 2024 08:34 am | GENERAL |
| NEW YEAR LETTER TO INVESTORS | Tue, Jan 09 2024 08:30 am | GENERAL |
| AFT broadens R&D pipeline with new product candidate | Fri, Dec 22 2023 08:49 am | GENERAL |
| AFT Pharma reports growth and global expansion | Thu, Nov 23 2023 08:34 am | HALFYR |
| AFT’s Crystaderm® antiseptic approved for sale in China | Tue, Nov 21 2023 08:30 am | GENERAL |
| AFT welcomes US FDA approval for sale of Maxigesic IV | Wed, Oct 18 2023 08:30 am | GENERAL |
| Retirement of Jon Lamb | Thu, Sep 28 2023 12:08 pm | ADMIN |
| AFT appoints Andrew Lane as independent director | Thu, Sep 28 2023 12:05 pm | ADMIN |
Major Holdings Announcements
| Date | Name | No. Held | % | Current |
|---|---|---|---|---|
| 16/09/20 | Forsyth Barr Group Limited and Fors | 1,617,818 | 71.25 | 1.55 |
| 15/06/20 | Hartley Campbell Atkinson and Colin | 72,031,609 | 72.60 | 69.82 |
| 15/06/20 | The CRG Persons | - | 15.99 | - |
| 25/05/17 | AFT Pharmaceuticals Limited | - | 72.34 | - |
Director’s Interests Announcements
| Date | Name | No. Held | % | Details | Other |
|---|---|---|---|---|---|
| 13/01/22 | Jon Lamb | 303,764 | - | - | - |
| 14/04/21 | Malcolm Tubby | 143,892 | - | - | - |
| 10/08/20 | Hartley Atkinson | 72,899,435 | - | - | - |
| 03/07/20 | David Flacks | 178,764 | - | - | - |
| 22/08/18 | James Burns | 125,417 | - | - | - |
| 19/06/17 | John Douglas Wilson | 56,689 | - | - | - |
Analysts’ Forecasts
| profit2021 | profit2022 | eps2021 | dps2021 | sales2021 | ebit2021 | ebitda2021 | |
|---|---|---|---|---|---|---|---|
| mean | 21.1 | 20.1 | 6.0 | 152.7 | 27.1 | 28.2 | |
| high | 21.1 | 20.1 | 6.0 | 152.7 | 27.1 | 28.2 | |
| low | 21.1 | 20.1 | 6.0 | 152.7 | 27.1 | 28.2 | |
| sample | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
Disclaimer
Markets News
Pushpay investors ponder takeover as NZX50 marches on
Yield stocks such as Chorus and property investors led the market higher.
Paul McBeth: Building a property portfolio with Winton
Here's a way the Sharesies generation can get their fill of property.
Morningstar picks Spark as omicron refuge
Spark’s share price spiked more than 5% early this week as investors reacted to news of the variant, but it had been trending down, sliding more than 10% in the past three months.
It's happening – Ikea coming to Sylvia Park
Ikea is finally landing in New Zealand. Really.
Winton delivers early Christmas present to NZX in $350m IPO
Macquarie will take a big piece of the action in Winton's Christmas initial public offering.
